- Home
- CMS vs DGX Comparison
CMS vs DGX Comparison
Compare CMS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMS | DGX |
|---|---|---|
| Founded | 1987 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2B | 20.5B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CMS | DGX |
|---|---|---|
| Price | $69.75 | $182.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $79.08 | ★ $194.07 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 10-30-2025 | 01-29-2026 |
| Dividend Yield | ★ 3.11% | 1.75% |
| EPS Growth | N/A | ★ 14.49 |
| EPS | 3.47 | ★ 8.51 |
| Revenue | $8,295,000,000.00 | ★ $10,850,000,000.00 |
| Revenue This Year | $9.21 | $12.37 |
| Revenue Next Year | $3.75 | $3.52 |
| P/E Ratio | ★ $20.13 | $21.44 |
| Revenue Growth | 10.96 | ★ 13.74 |
| 52 Week Low | $63.97 | $148.70 |
| 52 Week High | $76.45 | $197.55 |
Technical Indicators
Market Signals| Indicator | CMS | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 46.92 |
| Support Level | $69.33 | $178.61 |
| Resistance Level | $70.65 | $185.12 |
| Average True Range (ATR) | 1.03 | 2.71 |
| MACD | -0.43 | -0.73 |
| Stochastic Oscillator | 9.54 | 25.99 |
Price Performance
Historical ComparisonAbout CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.